Anemocyte to expand its plasmid manufacturing capabilities

A new state-of-the-art facility dedicated to plasmid manufacturing will be in operation by August 2019 in Gerenzano, Italy.

The new site will couple with the existing GMP facility active in the Cell and Gene (C&G) therapy space.

With 800m2 (8,000 square feet) of cleanrooms, the two facilities of Anemocyte, the first Biotech Manufacturing Organisation (BMO), will address manufacturing needs of Somatic Cells, Non-Viral Modified Cells, Vesicles and Plasmids for Viral Vectors.

The new Plasmid Manufacturing Unit will replace the existing one allowing production of R&D, High Quality and GMP plasmids addressing all applications: from discovery research through commercial production.

Mentioned Companies

Anemocyte S.r.l.